Amicus Therapeutics, Inc. (0HF9.L)
| Previous close | 9.38 |
| Open | 9.62 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 9.62 - 9.62 |
| 52-week range | 9.62 - 14.57 |
| Volume | |
| Avg. volume | 814 |
| Market cap | 28.199M |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.97 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksAmicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksAmicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 66.67% and 1.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireAmicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
1Q 2024 Total Revenue of $110.4M, a 28% Increase Year-over-Year Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at CER Raising Full-Year 2024 Galafold® Guidance on Continued Strong Demand Strong Pombiliti® + Opfolda® Launch with Increasing Rate of Commercial Patient Starts Reiterating Full-Year Non-GAAP Profitability Projected in 2024 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicat
